CANCER DISCOVERY CONTENTS

APRIL 2012 ▪ VOLUME 2 ▪ NUMBER 4







For more News and Research Watch, visit *Cancer Discovery* online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

- The 24-hour, $1,000 Genome
- Delivering Quantum Dot Probes into the Cytosol
- DNA Nanorobot Signals Cancer Cells to Die
- Reporter Works with Multiple Imaging Types

ON THE COVER Ulmert and colleagues developed ^{89}Zr-5A10, a radiolabeled monoclonal antibody that targets tumor-associated "free" prostate-specific antigen (PSA). The ^{89}Zr-5A10 radiotracer selectively and noninvasively detected and visualized prostate cancer xenografts and bone lesions, and could quantitatively measure changes in PSA production in response to antiandrogen therapy. These findings have implications for the clinical assessment of advanced prostate cancer and the evaluation of experimental therapies. For details, please see the article by Ulmert and colleagues on page 320.

AACR American Association for Cancer Research

CANCER DISCOVERY

2 (4)

Cancer Discovery 2012;2:OF9-376.